La cadena de opciones muestra datos clave de las opciones de acciones de Stereotaxis a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Stereotaxis..

Stereotaxis (AMEX:STXS) Bolsa, Cadena de Opciones

Stereotaxis

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service and accessories stream. The company generates the majority of revenue from the United States.

Stereotaxis Inc

Stereotaxis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STXS#NYSE">STXS</a>) and Shanghai MicroPort EP Medtech Co., Ltd. (688351.SH, "MicroPort EP"), today announced that the Magbot&#x2122; Magnetic Navigation Ablation Catheter has received regulatory approval from China's National Medical Products Administration (NMPA).
The Magbot&#x2122; Catheter is a single-use magnetic saline-irrigated radiofrequency ablation catheter designed and developed by MicroPort EP in collaboration with Stereotaxis. The catheter works exclusively and in tight conjunction with Stereotaxis' robotic systems, including the recently NMPA-approved Genesis RMN&#x2122;, and MicroPort EP's Columbus&#x2122; 3D EP Mapping System.
Magbot&#x2122; incorporates advanced design features that substantially enhance the efficiency, effectiveness, and safety of robotic magnetic catheter ablation. Robotically navigated using low-intensity magnetic fields, the Magbot&#x2122; catheter is able to reach areas of the heart otherwise difficult to access with traditional methods and to maintain precise positioning and stability on cardiac anatomy with millimeter-level accuracy. Full integration with Columbus&#x2122; enables real-time location tracking and 3D cardiac modeling, allowing physicians to accurately record electrocardiographic data and pinpoint lesions for precise diagnosis and treatment of arrhythmias. A unique six-electrode design enhances safety during procedures by offering visibility of the catheter shaft without the need for fluoroscopy. Magbot&#x2122; has been approved by NMPA for the ablation of drug-resistant persistent atrial fibrillation, atrioventricular nodal reentrant tachycardia, and atrioventricular reentrant tachycardia.

Government

News

Regulations

STXS

Stereotaxis and MicroPort EP Secure NMPA Approval for Magbot Ablation Catheter in China

Stereotaxis Genesis Robotic System Secures Regulatory Approval In China, Marking Key Milestone In Partnership With MicroPort EP For Commercial Launch Of Advanced Robotic And Electrophysiology Solutions

Stereotaxis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STXS#NYSE">STXS</a>), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at the Hospital da Luz in Lisbon, Portugal have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System.
"We are excited to be at the forefront of technology and patient care by introducing the new Genesis System at Hospital da Luz," said Prof. Pedro Adragão, Cardiac Electrophysiologist at Hospital da Luz. "Robotics allows us to treat patients with effective individualized therapy and the highest focus on safety. We are pleased to offer this high-level care to all our patients, including those with the most complex arrhythmia. We also are pleased to continue advancing this important technology for the benefit of patients and medical progress."

Global

Stereotaxis Announces That Physicians At The Hospital Da Luz In Lisbon, Portugal Have Successfully Treated The First Patients Using The Advanced Genesis Robotic Magnetic Navigation System

Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.05) by 60 percent. The company reported quarterly sales of $9.196 million which beat the analyst consensus estimate of $7.100 million by 29.52 percent. This is a 17.91 percent increase over sales of $7.799 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Stereotaxis Q3 2024 GAAP EPS $(0.08) Misses $(0.05) Estimate, Sales $9.196M Beat $7.100M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Global Ship Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSL#NYSE">GSL</a>) is projected to report quarterly earnings at $2.41 per share on revenue of $174.31 million. 
• Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) is projected to report quarterly earnings at $0.63 per share on revenue of $246.09 million. 
• Aramark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARMK#NYSE">ARMK</a>) is likely to report quarterly earnings at $0.53 per share on revenue of $4.46 billion. 
• ICL Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICL#NYSE">ICL</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $2.03 billion. 
• Lincoln Educational Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINC#NASDAQ">LINC</a>) is projected to report quarterly earnings at $0.09 per share on revenue of $110.77 million. 
• Strawberry Fields REIT (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STRW#AMEX">STRW</a>) is estimated to report earnings for its third quarter. 
• Sapiens Intl Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPNS#NASDAQ">SPNS</a>) is projected to report quarterly earnings at $0.38 per share on revenue of $140.07 million. 
• Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) is projected to report quarterly loss at $1.28 per share on revenue of $2.36 million. 
• GEO Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) is estimated to report earnings for its third quarter. 
<h3>Companies Reporting After The Bell</h3>
• Grab Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) is expected to report quarterly loss at $0.01 per share on revenue of $691.80 million. 
• Ispire Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPR#NASDAQ">ISPR</a>) is estimated to report quarterly loss at $0.05 per share on revenue of $52.81 million. 
• Talos Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TALO#NYSE">TALO</a>) is estimated to report quarterly loss at $0.05 per share on revenue of $500.03 million. 
• Team (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TISI#NYSE">TISI</a>) is estimated to report earnings for its third quarter. 
• Mineralys Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>) is expected to report earnings for its third quarter. 
• Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) is likely to report quarterly earnings at $1.71 per share on revenue of $8.09 billion. 
• Gatos Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GATO#NYSE">GATO</a>) is projected to report earnings for its third quarter. 
• Yalla Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YALA#NYSE">YALA</a>) is likely to report earnings for its third quarter. 
• Archrock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AROC#NYSE">AROC</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $283.55 million. 
• Ampco-Pittsburgh (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AP#NYSE">AP</a>) is likely to report earnings for its third quarter. 
• FGI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGI#NASDAQ">FGI</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $30.69 million. 
• Bioceres Crop Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOX#NASDAQ">BIOX</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $120.80 million. 
• RMR Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMR#NASDAQ">RMR</a>) is estimated to report quarterly earnings at $0.38 per share on revenue of $220.35 million. 
• Assertio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASRT#NASDAQ">ASRT</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $28.87 million. 
• Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) is projected to report quarterly loss at $0.28 per share on revenue of $1.04 million. 
• Bridger Aerospace Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) is estimated to report quarterly earnings at $0.46 per share on revenue of $57.50 million. 
• Aterian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) is expected to report quarterly loss at $0.55 per share on revenue of $26.01 million. 
• QuickLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUIK#NASDAQ">QUIK</a>) is likely to report quarterly loss at $0.05 per share on revenue of $4.20 million. 
• VAALCO Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EGY#NYSE">EGY</a>) is estimated to report quarterly earnings at $0.17 per share on revenue of $145.89 million. 
• Assured Guaranty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGO#NYSE">AGO</a>) is projected to report quarterly earnings at $1.36 per share on revenue of $201.37 million. 
• Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) is likely to report quarterly loss at $0.05 per share on revenue of $7.10 million. 
• NET Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPWR#NYSE">NPWR</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $3.00 million. 
• Luminar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) is expected to report quarterly loss at $0.17 per share on revenue of $18.68 million. 
• James River Gr Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JRVR#NASDAQ">JRVR</a>) is estimated to report quarterly earnings at $0.15 per share on revenue of $146.56 million. 
• Crescent Capital BDC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCAP#NASDAQ">CCAP</a>) is estimated to report quarterly earnings at $0.57 per share on revenue of $48.69 million. 
• IAC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>) is estimated to report quarterly loss at $0.28 per share on revenue of $923.69 million. 
• Angi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $298.54 million. 
• Intevac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVAC#NASDAQ">IVAC</a>) is expected to report quarterly loss at $0.15 per share on revenue of $11.50 million. 
• Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) is likely to report quarterly loss at $0.81 per share on revenue of $93.07 million. 
• Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) is likely to report quarterly earnings at $0.17 per share on revenue of $248.65 million. 
• DoubleDown Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDI#NASDAQ">DDI</a>) is estimated to report quarterly earnings at $0.55 per share on revenue of $85.43 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANGI

ARMK

AROC

ASRT

ATER

BAER

BIOX

CCAP

GATO

GRAB

ISPR

IVAC

JRVR

LAZR

LINC

MLYS

MNDY

NPWR

NUWE

NVRO

QUIK

SPNS

STRW

TALO

TISI

XAIR

YALA

ZETA

Earnings Scheduled For November 11, 2024

Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) will release its quarterly earnings report on Monday, 2024-11-11. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Stereotaxis to report an earnings per share (EPS) of $-0.05.
Anticipation surrounds Stereotaxis's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings Track Record</h3>
Last quarter the company missed EPS by $0.02, which was followed by a 11.67% increase in the share price the next day.
Here's a look at Stereotaxis's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.05</td>
<td>-0.06</td>
<td>-0.07</td>
<td>-0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.07</td>
<td>-0.06</td>
<td>-0.07</td>
<td>-0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>12.0%</td>
<td>-3.0%</td>
<td>-7.000000000000001%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731081819_0.png" alt="eps graph" />
<h3>Tracking Stereotaxis's Stock Performance</h3>
Shares of Stereotaxis were trading at $1.84 as of November 07. Over the last 52-week period, shares are up 31.25%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/STXS/earnings">To track all earnings releases for Stereotaxis visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Stereotaxis Earnings Preview

Health Care

General

Stereotaxis Announces University Of Kansas Medical Center Physicians Have Treated The First Patients Using The Company's Genesis Robotic Magnetic Navigation System

Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. The company reported quarterly sales of $4.502 million which missed the analyst consensus estimate of $5.625 million by 19.96 percent. This is a 42.72 percent decrease over sales of $7.859 million the same period last year.

Stereotaxis Q2 2024 GAAP EPS $(0.07) Misses $(0.05) Estimate, Sales $4.502M Miss $5.625M Estimate

WIIM

Stereotaxis shares are trading higher after the company achieved CE Mark approval in Europe and submitted a 510(k) application to the FDA for its GenesisX Robotic System.

Stereotaxis Achieves CE Mark In Europe And Submits 510(k) To FDA For GenesisX Robotic System

AxoGen (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axgn#NASDAQ">AXGN</a>)&nbsp;came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 200%. A quarter ago, it was expected that this regenerative medicine company would post a loss of $0.10 per share when it actually produced a loss of $0.06, delivering a surprise of 40%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
AxoGen, which belongs to the Zacks Medical - Instruments industry, posted revenues of $47.91 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 10.74%. This compares to year-ago revenues of $38.16 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock&#39;s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management&#39;s commentary on the earnings call.
AxoGen shares have added about 16% since the beginning of the year versus the S&amp;P 500&#39;s gain of 9%.
<h2>What&#39;s Next for AxoGen?</h2>
While AxoGen has outperformed the market so far this year, the question that comes to investors&#39; minds is: what&#39;s next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company&#39;s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for AxoGen: mixed. While the magnitude and direction of estimate revisions could change following the company&#39;s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.03 on $46.27 million in revenues for the coming quarter and -$0.19 on $178.53 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Stereotaxis Inc. (AMEX:STXS), has yet to report results for the quarter ended June 2024. The results are expected to be released on August 12.
This company is expected to post quarterly loss of $0.04 per share in its upcoming report, which represents a year-over-year change of +42.9%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Stereotaxis Inc.&#39;s revenues are expected to be $5.7 million, down 27.5% from the year-ago quarter.
<a href="https://www.zacks.com/stock/news/2318917/axogen-axgn-q2-earnings-and-revenues-beat-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-2318917">To read this article on Zacks.com click here.</a>

Biotech

Penny Stocks

Small Cap

Markets

Analyst Ratings

Trading Ideas

AXGN

AxoGen Q2 Earnings and Revenues Beat Estimates

The Dow Jones index closed higher by around 0.5% on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Stereotaxis</h3>
<ul>
<li>The Trade: Stereotaxis, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STXS#NYSE">STXS</a>) Director Paul J Isaac <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 7,000 shares</a> at an average price of $1.86. To acquire these shares, it cost around $13,017.</li>
<li>What's Happening: On May 13, Stereotaxis posted weaker-than-expected quarterly sales.</li>
<li>What Stereotaxis Does: Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures.</li>
</ul>
<h3 class="wp-block-heading">Mobile Infrastructure</h3>
<ul>
<li>The Trade: Mobile Infrastructure Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEEP#NYSE">BEEP</a>) Director Jeffrey Osher <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 5,983 shares at</a> at an average price of $3.30. To acquire these shares, it cost around $19,750.</li>
<li>What's Happening: On May 15, Mobile Infrastructure named Paul Gohr as new CFO.</li>
<li>What Mobile Infrastructure Does: Mobile Infrastructure Corp focuses on acquiring, owning, and leasing parking facilities and related infrastructure, including parking lots, parking garages and other parking structures throughout the United States.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/06/39355507/jim-cramer-says-hes-going-to-have-to-wait-on-sofi-but-recommends-this-great-little-indus">Jim Cramer Says He&#8217;s &#8216;Going To Have To Wait&#8217; On SoFi, But Recommends This &#8216;Great Little Industrial Company&#8217;</a>
<h3 class="wp-block-heading">Hyliion Holdings</h3>
<ul>
<li>The Trade: Hyliion Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HYLN#NYSE">HYLN</a>) Chief Commercial Officer Govindaraj Ramasamy <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 10,000 shares</a> at an average price of $1.50. The insider spent around $15,000 to buy those shares. </li>
<li>What's Happening: On June 5, Hyliion announced commencement of manufacturing of additive parts for KARNO Generator at Austin Headquarters.</li>
<li>What Hyliion Holdings Does: Hyliion Holdings Corp is a provider of electrified solutions for the commercial vehicle industry as well as other industries.</li>
</ul>
<h3 class="wp-block-heading">FlexShopper</h3>
<ul>
<li>The Trade: FlexShopper, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FPAY#NASDAQ">FPAY</a>) Director Howard Dvorkin <a href="https://www.benzinga.com/quote/FPAY/analyst-ratings">acquired a total of 12,845 shares</a> at an average price of $1.22. The insider spent around $15,621 to buy those shares.</li>
<li>What's Happening: On May 13, FlexShopper posted upbeat quarterly sales.</li>
<li>What FlexShopper Does: FlexShopper Inc is a financial technology company engaged in providing certain types of durable goods to consumers on a lease-to-own basis and providing lease-to-own (LTO) terms to consumers of third-party retailers and e-tailers.</li>
</ul>
Don&#8217;t forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>

Long Ideas

Insider Trades

Pre-Market Outlook

Mobile Infrastructure Corporation Common Stock

BEEP

FPAY

HYLN

Hyliion Holdings And 3 Other Penny Stocks Insiders Are Buying

Stereotaxis Announces Penn Presbyterian Medical Center First Treats First Heart Rhythm Patients Using Genesis Robotic Magnetic Navigation System.

<a href="https://www.globenewswire.com/Tracker?data=v-8lZrL3Hbg-65FBgwZmSe4WzqRDScfhn5dMio0G2vQys3Nafm__mMXmrwMlbhudGeKCk_gacXahjI-zyZMg7g==">Stereotaxis</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STXS#NYSE">STXS</a>), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received CE Mark recertification under the European Union's new Medical Device Regulation (MDR) regulatory framework. The recertification under MDR covers all Stereotaxis devices currently available in Europe.

Stereotaxis Receives CE Mark Recertification Under EU's Medical Device Regulation Regulatory Framework

Stereotaxis Announces First Heart Rhythm Patients Treated With Robotic Ablation Procedures

<a href="https://www.globenewswire.com/Tracker?data=G0XsXOBib56JXFkySwt2mUU5_GpoSoP-lT9tomrgnGGR3V1q3BpbV3fedVYG9PehJDbIKw3c1CSnd5dQM8VJFg==">Stereotaxis</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STXS#NYSE">STXS</a>), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has been invited to present at HRS Africa Summit 2024, scheduled to take place during Heart Rhythm Society Scientific Sessions this week in Boston, Massachusetts. &nbsp;
Stereotaxis will present an innovative proposal leveraging advanced robotic technology and telerobotic presence to sustainably offer high-quality cardiac ablation therapy in underserved regions of Africa. Africa is the second most populous and fastest growing continent, and yet has a nearly non-existent infrastructure of electrophysiology (EP) labs to provide cardiac ablation therapy. Cardiac ablation is a common minimally invasive procedure to treat arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, arrhythmias may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest. Eighty percent of African countries do not have a single functional EP labi.

Stereotaxis Invited By Africa Heart Rhythm Association To Present its Robotic Solution To Expand High-Quality Therapy In Africa

Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 14.29 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $6.880 million which missed the analyst consensus estimate of $7.000 million by 1.71 percent. This is a 5.07 percent increase over sales of $6.548 million the same period last year.

Stereotaxis Q1 2024 GAAP EPS $(0.06), Inline, Sales $6.880M Miss $7.000M Estimate

Stereotaxis Signs Definitive Agreement To Acquire Access Point Technologies

Lake Street analyst Frank Takkinen maintains Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) with a Buy and raises the price target from $3 to $4.

Price Target

Lake Street Maintains Buy on Stereotaxis, Raises Price Target to $4

Roth MKM analyst Jason Wittes reiterates Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) with a Buy and maintains $5 price target.

Reiteration

Roth MKM Reiterates Buy on Stereotaxis, Maintains $5 Price Target

Stereotaxis ( ($STXS) ) has released its Q3 earnings. Here is a breakdown of the information Stereotaxis presented to its investors. Stereotaxis, a...

Stereotaxis Reports Strong Q3 Growth in Robotics

Piper Sandler analyst Adam Maeder assigned a Buy rating to Stereotaxis (STXS – Research Report) today and set a price target of $4.00. The company'...

Piper Sandler Releases a Buy Rating on Stereotaxis (STXS)

Stereotaxis (STXS) announced regulatory approval of the Genesis RMN System by China's National Medical Products Administration. This approval is a ...

Stereotaxis' Genesis RMN System achieves regulatory approval in China

Lake Street analyst Frank Takkinen reiterated a Buy rating on Stereotaxis (STXS – Research Report) today and set a price target of $4.00. The compa...

Lake Street Keeps Their Buy Rating on Stereotaxis (STXS)

In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Stereotaxis (STXS – Research Report), with a price target of $5....

Strategic Partnerships and Regulatory Advancements Propel Stereotaxis to Buy Rating

Stereotaxis To Drive Transformational Growth Via Full Ecosystem Launch In 2025

Stereotaxis (STXS) and Neusoft Medical Systems announced that Stereotaxis' latest GenesisX robotic system is being featured for the first time at N...

Stereotaxis to showcase GenesisX Robotic System at RSNA 2024

Stereotaxis (STXS) and Shanghai MicroPort EP Medtech announced that the Magbot Magnetic Navigation Ablation Catheter has received regulatory approv...

Stereotaxis, Medtech announce catheter approved by China's NMPA

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Stereotaxis (STXS – Research Report), BioNTech SE (B...

Analysts Offer Insights on Healthcare Companies: Stereotaxis (STXS), BioNTech SE (BNTX) and Kymera Therapeutics (KYMR)

Analyst Josh Jennings from TD Cowen maintained a Buy rating on Stereotaxis (STXS – Research Report) and keeping the price target at $5.00. Josh Jen...

Comments

Stereotaxis

Stereotaxis (STXS) Opciones

Stereotaxis (AMEX:STXS) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL